PharmExec - Pharmaceutical Executive
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
Financial Times Global Pharma and Biotech Summit: The Impact of …
2024年11月7日 · Donald Trump’s victory in the 2024 US presidential election is sure to have an impact on the pharmaceutical industry. During a panel at the Financial Times’ 2024 Global …
2024 Pharm Exec Top 50 Companies
2024年6月14日 · Highlighted by notable company and product maneuvering at the top and the continued dramatic growth of therapeutic settings such as GLP-1s, Pharm Exec’s latest listing …
Pharmaceutical Executive - PharmExec
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
Driving Innovation: How Collaboration Between Medical Affairs …
2024年5月10日 · In the rapidly evolving healthcare industry, pharmaceutical companies must adapt and leverage their internal resources to stay competitive while delivering innovative …
Don Tracy, Associate Editor - PharmExec
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
A Promising Option: Exxua - PharmExec
2024年8月16日 · After being rejected five times by regulators over two decades, Exxua (gepirone extended-release), long heralded as a potential breakthrough in mental health treatment, …
About Us - PharmExec
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
Pharmaceutical Executive APEX Awards - PharmExec
We’re proud to celebrate a fourth year of spotlighting creative from our industry’s best. Competition is fierce and trophies are hard-earned. The best part? We all come together for a …
Arrivent’s Furmonertinib Receives FDA Breakthrough ... - PharmExec
2023年11月1日 · ArriVent Biopharma, Inc. announced that the FDA has granted breakthrough therapy designation to furmonertinib for the treatment of patients with previously untreated, …